Valuation, from the filing
| Public float | $367.00B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-29 |
|---|---|---|
| Float per share | $152.29 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 13.7× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 3.9× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 4.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-29, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-28 — the year that filing covered.
Valuation over time
13.7× earnings today, against a median of 22.8× across 10 years on record. Below its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-29 | $367.00B | 13.7× | |
| 2024-06-30 | $352.00B | 25.0× | |
| 2023-07-02 | $430.00B | 12.2× | |
| 2022-07-03 | $472.00B | 26.3× | |
| 2021-07-04 | $445.00B | 21.3× | |
| 2020-06-28 | $363.00B | 24.7× | |
| 2019-06-30 | $368.00B | 24.3× | |
| 2018-07-01 | $325.00B | 21.2× | |
| 2017-07-02 | $332.00B | 255.4× | |
| 2016-07-03 | $332.00B | 20.1× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| R&D / revenue | 0.1% | 0th | |
| SBC / revenue | 1.4% | 9th | |
| Net margin | 28.5% | 90th | |
| FCF margin | 20.9% | 89th | |
| Current ratio | 1.03x | 16th | |
| CapEx / revenue | 5.1% | 67th | |
| Gross margin | 67.9% | 44th | |
| Long-term debt / equity | 0.48x | 46th | |
| Effective tax rate | 17.7% | 53th | |
| Revenue YoY growth | 6.0% | 53th |
JOHNSON & JOHNSON (JNJ) reported revenue of $25.40B and net income of $210.00M for the fiscal year ended 2026-09-27. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from JOHNSON & JOHNSON’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-09-27 | 2026-06-28 | 2026-03-29 | 2025-12-28 | 2025-09-28 | 2025-06-29 | 2025-03-30 | 2024-12-29 | 2024-09-29 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.40B | $25.31B | $24.06B | $24.56B | $23.99B | $23.74B | $21.89B | $22.52B | $22.47B | $22.45B |
| Cost of revenue | $8.10B | $8.05B | $8.11B | $7.97B | $7.30B | $7.63B | $7.36B | $7.13B | $6.96B | $6.87B |
| Gross profit | $17.30B | $17.26B | $15.96B | $16.60B | $16.69B | $16.12B | $14.54B | $15.39B | $15.51B | $15.58B |
| Operating income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net income | $210.00M | $5.53B | $5.24B | $5.12B | $5.15B | $5.54B | $11.00B | $3.43B | $2.69B | $4.69B |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 2.45B | shares 2.44B | shares 2.45B | Unavailable | shares 2.43B | shares 2.42B | shares 2.42B | Unavailable | shares 2.43B | shares 2.42B |
| Pretax income | $34.00M | $6.75B | $5.99B | $4.97B | $7.49B | $6.49B | $13.63B | $3.89B | $3.34B | $5.75B |
| Income tax expense | -$176.00M | $1.21B | $755.00M | -$150.00M | $2.34B | $954.00M | $2.63B | $456.00M | $644.00M | $1.06B |
| Diluted EPS | $0.09 | $2.27 | $2.14 | Unavailable | $2.12 | $2.29 | $4.54 | Unavailable | $1.11 | $1.93 |
| Selling, general & administrative | $6.28B | $6.43B | $6.03B | $6.75B | $5.92B | $5.89B | $5.11B | $6.45B | $5.48B | $5.68B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-09-27 | 2026-06-28 | 2026-03-29 | 2025-12-28 | 2025-09-28 | 2025-06-29 | 2025-03-30 | 2024-12-29 | 2024-09-29 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.91B | $20.42B | $21.69B | $19.71B | $18.23B | $18.58B | $38.47B | $24.10B | $19.98B | $24.88B |
| Total assets | $197.42B | $201.06B | $200.89B | $199.21B | $192.82B | $193.39B | $193.67B | $180.10B | $178.29B | $181.09B |
| Current assets | $56.35B | $59.77B | $59.17B | $55.62B | $54.61B | $54.50B | $71.55B | $55.89B | $53.25B | $57.82B |
| Total liabilities | $115.90B | $116.09B | $119.71B | $117.67B | $113.54B | $114.92B | $115.56B | $108.61B | $108.13B | $109.55B |
| Current liabilities | $55.46B | $54.90B | $57.72B | $54.13B | $50.87B | $54.18B | $56.90B | $50.32B | $51.76B | $53.93B |
| Total equity incl. NCI | $81.53B | $84.97B | $81.19B | $81.54B | $79.28B | $78.47B | $78.11B | $71.49B | $70.16B | $71.54B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $15.38B | $15.14B | $14.58B | $14.19B | $14.15B | $13.41B | $12.66B | $12.44B | $12.60B | $12.17B |
| Accounts receivable | $18.99B | $19.05B | $17.72B | $17.18B | $17.61B | $17.85B | $16.02B | $14.84B | $16.17B | $15.79B |
| Goodwill | $48.47B | $48.48B | $48.56B | $48.77B | $48.05B | $48.12B | $44.47B | $44.20B | $44.80B | $44.25B |
| Long-term debt | $35.80B | $37.34B | $37.53B | $39.44B | $39.41B | $39.24B | $38.36B | $30.65B | $31.29B | $31.64B |
| Accounts payable | $9.32B | $9.22B | $10.46B | $11.99B | $9.62B | $9.46B | $9.54B | $10.31B | $8.95B | $8.85B |
Cash flow
| Metric | 2026-09-27 | 2026-06-28 | 2026-03-29 | 2025-12-28 | 2025-09-28 | 2025-06-29 | 2025-03-30 | 2024-12-29 | 2024-09-29 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.72B | $8.62B | $2.51B | $7.31B | $9.17B | $3.88B | $4.17B | $6.98B | $7.99B | $5.63B |
| Capital expenditures | $1.36B | $1.32B | $1.05B | $1.84B | $1.16B | $1.04B | $795.00M | $1.61B | $1.03B | $976.00M |
| Investing cash flow | -$2.71B | -$1.11B | -$1.04B | -$4.48B | -$542.00M | -$18.26B | -$297.00M | -$1.32B | -$3.13B | -$13.69B |
| Financing cash flow | -$8.53B | -$8.78B | $530.00M | -$1.37B | -$8.93B | -$5.66B | $10.42B | -$1.34B | -$9.88B | $7.54B |
| Net change in cash | -$3.51B | -$1.27B | $1.98B | $1.48B | -$346.00M | -$19.90B | $14.37B | $4.12B | -$4.90B | -$595.00M |
| Stock-based compensation | $357.00M | $458.00M | $300.00M | $309.00M | $347.00M | $410.00M | $288.00M | $238.00M | $295.00M | $341.00M |
| Common dividends paid | $3.23B | $3.23B | $3.13B | $3.13B | $3.13B | $3.13B | $2.99B | $2.98B | $2.98B | $2.98B |
| Common share repurchases | $1.71B | $221.00M | $4.03B | $1.92B | $1.90B | $0 | $2.13B | $282.00M | $539.00M | $136.00M |
| Depreciation & amortization | $2.12B | $1.96B | $2.00B | $2.01B | $1.78B | $1.94B | $1.77B | $1.90B | $1.85B | $1.78B |
Derived
| Metric | 2026-09-27 | 2026-06-28 | 2026-03-29 | 2025-12-28 | 2025-09-28 | 2025-06-29 | 2025-03-30 | 2024-12-29 | 2024-09-29 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $6.36B | $7.30B | $1.46B | $5.47B | $8.01B | $2.84B | $3.38B | $5.37B | $6.96B | $4.66B |
| Gross margin | 68.1% | 68.2% | 66.3% | 67.6% | 69.6% | 67.9% | 66.4% | 68.3% | 69.0% | 69.4% |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | 25.0% | 28.8% | 6.1% | 22.3% | 33.4% | 11.9% | 15.4% | 23.8% | 31.0% | 20.7% |
| SBC / revenue | 1.4% | 1.8% | 1.2% | 1.3% | 1.4% | 1.7% | 1.3% | 1.1% | 1.3% | 1.5% |
| Current ratio | 1.02x | 1.09x | 1.03x | 1.03x | 1.07x | 1.01x | 1.26x | 1.11x | 1.03x | 1.07x |
| Revenue YoY growth | 5.9% | 6.6% | 9.9% | 9.1% | 6.8% | 5.8% | 2.4% | 5.3% | 5.2% | 4.3% |
| Net margin | 0.8% | 21.9% | 21.8% | 20.8% | 21.5% | 23.3% | 50.2% | 15.2% | 12.0% | 20.9% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 5.4% | 5.2% | 4.4% | 7.5% | 4.8% | 4.4% | 3.6% | 7.2% | 4.6% | 4.3% |
| Long-term debt / equity | 0.44x | Unavailable | Unavailable | 0.48x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | -517.6% | 18.0% | 12.6% | -3.0% | 31.2% | 14.7% | 19.3% | 11.7% | 19.3% | 18.5% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JNJ in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.